Acipimox
| 證據等級: L5 | 預測適應症: 0 個 |
目錄
Acipimox: Drug Repurposing Evaluation — No Predicted Indications Available
One-Sentence Summary
Acipimox is a nicotinic acid derivative (niacin analog) historically used as a lipid-lowering agent for the treatment of dyslipidaemia. The TxGNN model has not generated any repurposing predictions for this compound, and the drug is not currently marketed in the evaluated territory. Insufficient data is available to support a repurposing evaluation at this time.
Quick Overview
| Item | Content |
|---|---|
| Drug (INN) | Acipimox |
| DrugBank ID | DB09055 |
| Original Indication | Not recorded in evidence pack (known externally: dyslipidaemia / hyperlipidaemia) |
| Predicted New Indication | None — TxGNN returned no predictions |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 — No model prediction, no clinical evidence |
| Market Status | Not marketed (未上市) |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
No prediction has been generated by TxGNN for Acipimox. Therefore, this section cannot assess mechanistic plausibility for a new indication.
For context, Acipimox is a pyrazine derivative of nicotinic acid (niacin). It acts as a lipid-modifying agent that inhibits lipolysis in adipose tissue, leading to decreased circulating free fatty acids, reduced hepatic triglyceride synthesis, and lowered VLDL secretion. It also modestly raises HDL cholesterol. It was primarily used in Europe for the management of Type IIb and Type IV hyperlipoproteinaemia.
Currently, detailed mechanism of action data was not available in the evidence pack (flagged as Data Gap DG002). The absence of TxGNN predictions may be attributable to the drug’s limited presence in the knowledge graph or its narrow pharmacological profile. A DrugBank API query is recommended to enrich the MOA data before re-running the prediction pipeline.
Clinical Trial Evidence
Currently no related clinical trials are available, as no new indication has been predicted.
Literature Evidence
Currently no related literature is available for a repurposing direction, as no new indication has been predicted.
Market Information
Acipimox holds no marketing authorizations in the evaluated territory (Taiwan/TFDA). The drug is classified as not marketed (未上市).
| RVG/License Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| — | — | — | No licenses on record |
Note: Acipimox was historically marketed in several European countries (e.g., as Olbetam®) but has been discontinued or withdrawn in most markets.
Safety Considerations
Please refer to the SmPC (Summary of Product Characteristics) or the originator’s product documentation for safety information. All safety fields (key warnings, contraindications, and drug–drug interactions) are currently unavailable in the evidence pack.
Data gaps identified:
- TFDA label warnings and contraindications are unavailable (Data Gap DG001, severity: Blocking)
- No drug–drug interactions were found in the DDI database query
Data Gaps Summary
The following critical data gaps were identified and must be resolved before any repurposing evaluation can proceed:
| Gap ID | Category | Item | Severity | Recommended Remediation |
|---|---|---|---|---|
| DG001 | Drug Level | Label warnings / contraindications | Blocking | Download and parse product label PDF from regulatory authority |
| DG002 | Drug Level | Mechanism of Action (MOA) | High | Query DrugBank API for pharmacodynamic data |
| — | Prediction | TxGNN predicted indications | Blocking | Verify DrugBank ID mapping in knowledge graph; re-run prediction pipeline |
Conclusion and Next Steps
Decision: Hold
Rationale: Acipimox has no TxGNN-predicted repurposing indications, no active marketing authorization in the territory, and multiple blocking data gaps. There is currently no basis on which to evaluate a repurposing opportunity.
To proceed, the following is needed:
- Resolve DG002: Retrieve detailed MOA and pharmacological target data from DrugBank to enrich the knowledge graph
- Verify that Acipimox (DB09055) is correctly represented in the TxGNN knowledge graph (
data/kg.csv) and re-run the prediction pipeline - Resolve DG001: Obtain safety data from the originator’s SmPC or EMA assessment reports (Olbetam® historical dossier)
- Assess whether the drug’s discontinued status in most markets makes repurposing commercially viable before investing further analytical effort
- If predictions are generated upon re-run, collect clinical trial and literature evidence via ClinicalTrials.gov and PubMed collectors
⚠️ Disclaimer: This report is for research purposes only and does not constitute medical advice. Any drug repurposing candidates require clinical validation before therapeutic application.
🤖 Generated with Claude Code — Data cutoff: 2026-04-03
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.